Thermo fisher scientific signs companion diagnostic agreement with boehringer ingelheim to select patients with nsclc for targeted therapy treatment

Carlsbad, calif.--(business wire)--to support emerging precision therapies and improve patient outcomes by increasing access to reliable genomic testing needed to match patients with targeted cancer treatments, thermo fisher scientific today announced a companion diagnostic (cdx) partnership with boehringer ingelheim. through this collaboration, the companies will work to develop cdx tests to help identify patients with non-small cell lung cancer (nsclc) with specific genomic mutations. lung ca.
TMO Ratings Summary
TMO Quant Ranking